Pfizer da BioNTech sun yi nasarar samar da rigakafin Coronavirus

Allurar rigakafin da hadin gwiwar kamfanonin Pfizer da BioNTech ya samar, ya cimma nasarar kaiwa matakin kashi 90 na warkar da cutar coronavirus, kamar yadda kamfanonin suka sanar a baya bayan nan.

Hadin gwiwar Pfizer da BioNTech kan gwajin alluran rigakafin cutar coronavirus ya samu nasara REUTERS/Dado Ruvic/Illustration/File Photo

Yanzu haka dai an soma rige-rige tsakanin hukumomi ciki har da kungiyar EU, wajen sayen alluran rigakafin.

Kwakkyawan labarin nasarar gwajin allurar rigakafin ta BNT162b2 ya zo ne a daidai lokacin da aka sake samun hauhawar yawan mutanen da suka kamu da annobar ta coronavirus a sassan duniya musamman a Amurka da Turai, abinda ya tilastawa hukumomi a nahiyar sake killace miliyoyin mutane don dakile cutar da ta sake barkewa a karo na 2.

Sakamakon binciken farko da kwararru suka wallafa, ya nuna cewar marasa lafiya daga jinsin kabilu daban daban guda 28 da kamfanonin na Pfizer da BioNTech ke gwaji kansu, sun samu kariya daga annobar coronavirus bayan kwanaki 28 da basu allurer rigakafi guda guda da suka samar, yayinda kashin marasa lafiyar na biyu suka samu kariya daga cutar kwanaki 7, bayan yi musu allurar rigakafin sau 2.

Yanzu haka dai kamfanonin na BioNTech da Pfizer sun ce suna sa ran samar da alluran rigakafin coronavirus miliyan 50 kafin karshen shekara, za kuma su samar da karin alluran akalla biliyan 1 da miliyan 300 a shekarar 2021 mai kamawa.

Yanzu haka dai kungiyar kasashen Turai EU na gaf da kulla yarjejeniya da fitattun kamfanonin hada magungunan don sayen alluran rigakafin cutar ta coronavirus miliyan 300.